BNP Paribas Financial Markets lowered its stake in shares of HUTCHMED (China) Limited (NASDAQ:HCM - Free Report) by 32.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 39,643 shares of the company's stock after selling 18,800 shares during the quarter. BNP Paribas Financial Markets' holdings in HUTCHMED were worth $571,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors have also modified their holdings of HCM. Summit Trail Advisors LLC increased its holdings in shares of HUTCHMED by 14.4% in the 4th quarter. Summit Trail Advisors LLC now owns 13,090 shares of the company's stock valued at $189,000 after acquiring an additional 1,647 shares during the period. Crossmark Global Holdings Inc. grew its holdings in shares of HUTCHMED by 10.7% during the fourth quarter. Crossmark Global Holdings Inc. now owns 18,591 shares of the company's stock worth $268,000 after buying an additional 1,799 shares during the last quarter. Barclays PLC raised its stake in HUTCHMED by 1,483.6% during the 4th quarter. Barclays PLC now owns 2,407 shares of the company's stock valued at $35,000 after acquiring an additional 2,255 shares during the last quarter. Blue Trust Inc. raised its stake in shares of HUTCHMED by 99.9% during the fourth quarter. Blue Trust Inc. now owns 7,068 shares of the company's stock worth $102,000 after purchasing an additional 3,532 shares during the last quarter. Finally, OLD Mission Capital LLC acquired a new stake in shares of HUTCHMED during the fourth quarter worth $230,000. Hedge funds and other institutional investors own 8.82% of the company's stock.
HUTCHMED Trading Up 0.1%
Shares of HCM traded up $0.01 during mid-day trading on Tuesday, hitting $13.41. The company's stock had a trading volume of 49,173 shares, compared to its average volume of 101,220. The company has a quick ratio of 2.68, a current ratio of 2.81 and a debt-to-equity ratio of 0.07. HUTCHMED has a 1-year low of $11.51 and a 1-year high of $21.50. The firm has a 50-day simple moving average of $14.21 and a 200 day simple moving average of $14.94.
Analyst Upgrades and Downgrades
Several brokerages have issued reports on HCM. HSBC cut shares of HUTCHMED from a "buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Wall Street Zen lowered shares of HUTCHMED from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 22nd.
Read Our Latest Stock Analysis on HCM
HUTCHMED Profile
(
Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Read More
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
